R-enantiomer of N-propargyl-1-aminoindan, salts, compositions an

Details R-enantiomer of N-propargyl-1-aminoindan, salts, compositions an R-enantiomer of N-propargyl-1-aminoindan, salts, compositions an

1995-03-28

1996-07-02

Hollrah, Glennon H.

Organic compounds -- part of the class 532-570 series

Organic compounds

Amino nitrogen containing

C07C21138

Patent

active

055324150

ABSTRACT:
The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.

REFERENCES:
patent: 3201470 (1965-08-01), Huebner
patent: 3253037 (1966-05-01), Huebner
patent: 3513244 (1970-05-01), Gittos et al.
patent: 4826875 (1989-05-01), Chiesi
Finberg and Youdim, Modification of blood pressure and nictitating membrane response to symphathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat, British J. Pharmac. (Jun. 1985) 85(2):541-546 (Exhibit E).
Kabins and Gershon, Potential applications for monoamine oxidase B inhibitors Dementia (1990) 1:323-348 (Exhibit F).
The Merck Index (Tenth ed. 1983) pp. 149, 248-249 (Exhibit G).
The Parkinson Study Group, Effect of deprenyl on the progression of disability in early Parkinson's disease, New England J. Med. (1989) 321(20):1364-1371 (Exhibit H).
The Parkinson Study Group, Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease, New England J. Med. (Jan. 21, 1993) 328(3):176-183 (Exhibit I).
Riederer and Youdim, Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with 1-deprenyl, J. Neurochem. (1986) 46(5):1359-1365 (Exhibit J).
Tekes, et al., Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain, Pol. J. Pharmacol. Pharm. (1988) 40:653-658 (Exhibit K).
Youdim et al. in Handbook of Experimental Pharmacology vol. 90/I (1988) Chapter 3, Trendelenburg and Weiner, eds. (Exhibit L).

Affiliated with

Also associated with

Rating

R-enantiomer of N-propargyl-1-aminoindan, salts, compositions an does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with R-enantiomer of N-propargyl-1-aminoindan, salts, compositions an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and R-enantiomer of N-propargyl-1-aminoindan, salts, compositions an will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1507767